Mysterious Fog in the US , Canada and UK: A dense, eerie fog with a "burning chemical-like smell" has spooked a good part of North America and parts of the United Kingdom and Canada. With social media amplifying all concerns, this phenomenon has sparked attention across all social media platforms. However, at the heart of this mysterious fog are a conjunction of natural events, social psychology, and environmental conditions that culminated in all the conspiracy theories and public health fears. Here's a closer look at the mysterious fog, its potential causes, and the societal response it has triggered.

Fog that Feeds Fear

The first reports of this "mysterious fog" came in from Florida where a resident said that they experienced respiratory symptoms, feverish warmth, and stomach cramps after contact with the fog. Similar stories started flooding social media, and within a day or two, a sinister force seemed to sweep across the United States, Canada, and parts of the UK. From Texas to Minnesota, people reported weird odors and health issues that they thought were linked to this bizarre atmospheric event.

Some witnesses were said to see "white particles" swirling through the air; theories ranged from a chemical attack or experimental weapon to drone-related chemical dispersals and references to historical military experiments, such as the infamous 1950s "Operation Sea-Spray."

Fuel to the fire were added when videos and posts, hundreds of thousands in number, began circulating on social media sites like TikTok and X (formerly Twitter) speculating on the origin of the fog. Hashtags like #ToxicFog went trending for days. Hysteria created a self-reinforcing loop in which every post spurred further scrutiny and fear.

Scientific Explanation of the Dense Mysterious Fog

1. What is Fog?

Fog is essentially a low-lying cloud formed when the air temperature cools to its dew point, causing water vapor to condense into tiny droplets or ice crystals. Several types of fog—advection fog, radiation fog, and valley fog—can form depending on conditions such as warm, moist air moving over cooler land or when temperatures plummet rapidly under clear skies.

2. Why the Chemical Smell?

Such chemical-like smell as reported during the occurrence of fog events is sometimes attributed to air pollution. It acts like a sponge, where it absorbs these pollutants, which include sulfur dioxide and nitrogen oxides, among others, that emit from industries. This mixture, therefore, leads to a stench that could be mistaken as unnatural or even toxic.

Also Read: Health Concerns Rise As US, Canada, and UK Come Under The Blanket Of Thick, Dense, Toxic Fog

3. What are the Health Concerns?

High moisture levels from fog can significantly exacerbate symptoms related to respiration, but especially in already predisposed asthmatics and allergy patients. The connection of these symptoms with actual fever, stomach cramps, and puffy eyes is too remote. Experts assume that the irritating effects of entrapped pollutants trapped in fog tend to affect more the eyes and throat rather than the rest of the body affected by some report.

Psychological Effects of Mass Panic Caused by Social Media

Social media amplified a natural weather event into a health epidemic. It made the personal experience of individuals become a cause for fear and speculation, a domino effect.

According to psychologists, this is a concept of selective perception, wherein once people's attention is drawn to environmental anomalies, they begin to notice them. This mirrors earlier panics, such as the Seattle windshield pitting panic of 1954. Then, atomic bomb testing caused fear in many and started to have people looking at their windshields for small marks that they had not seen before. Likewise, postings on the strangeness of the fog probably increased public awareness and suspicion, with people looking to attach unrelated symptoms to the phenomenon.

The fog hysteria shares a commonality with other instances of mass panic, such as the "drone sightings" of recent years or the Cold War-era fears of biological warfare.

Also Read: Mysterious Fog Is Making Americans Sick

These events underscore how fear can cloud judgment, especially when amplified by social media and sensationalist headlines. While historical cases, such as "Operation Sea-Spray," offer concrete evidence of the existence of unethical experiments, the jump from a natural weather condition to theories of chemical attacks exemplifies a more modern trend of connecting unrelated dots, all wonderfully seeded in distrust and anxiety.

Despite the swirling rumors, meteorologists and scientists are in agreement that the mysterious fog is not as alarming as it seems. It is well known that fog traps and amplifies pollutants, especially in urban and industrial regions. Moreover, winter months are the most conducive for fog formation, so its recent prevalence is unsurprising.

On the other hand, environmentalists advise that the fog should wake everyone up to increased levels of pollution. The reported odors and health irritations could be just symptoms of far deeper systemic issues like industrial emissions and lack of control over air quality.

The authorities must be transparent in their communication to combat misinformation and allay public fears. Governments and environmental agencies must provide timely updates on weather phenomena, air quality, and health risks. Initiatives like real-time pollutant tracking and public education campaigns can help demystify natural occurrences while addressing valid environmental concerns.

The mysterious Canada fog is a compelling case study in how environmental events intersect with psychology and societal dynamics. While rooted in natural phenomena, the fog became a vessel for collective fears, amplified by modern technology and historical anxieties.

In this information era where communication occurs at an almost lightning pace, the fog becomes a metaphor that reminds everyone about scientific literacy, environmental responsibility, and an effective balance when considering public concern. Whether perceived as a marvel of nature or as a tale that serves to teach, it left a very powerful mark in people's minds.

reaImagine developing a strange medical condition in which an injury or even a minor fall may trigger a process that may gradually turn muscles, tendons and ligaments into bone.

This is what fibrodysplasia ossificans progressiva (FOP), one of the world’s rarest genetic disorders, looks like.

The US Food and Drug Administration recently approved a new treatment option for FOP called Atebrioz (zilurgisertib), a once-daily pill developed by Mirum Pharmaceuticals.

Adults and children aged 12 years and above with FOP are eligible for this treatment. It is designed to reduce the formation of new bone outside the skeleton.

What Is Fibrodysplasia Ossificans Progressiva?

FOP is a rare genetic disease in which connective tissues like muscles, tendons and ligaments gradually turn into bone. The abnormal bone formation is known as heterotopic ossification, meaning bone starts to develop in places where it should not.

Over time, this can pose restriction in movement, cause deformities and lead to severe disability. The condition could affect quality of life significantly as well as shorten life expectancy.

FOP is usually diagnosed in childhood. According to Mirum, around 300 people in the US and about 900 worldwide are known to have the condition.

Also read: New RNA Therapy For ALS, The Disease Stephen Hawking Had: Patient With Rare Motor Neuron Disease Improves

Why Does The Body Starts Making Bone In The Wrong Places?

FOP is caused by mutations in a gene involved in bone growth, especially the ACVR1 gene, which produces a protein called activin A receptor type-1, or ALK2. In people with FOP, this pathway becomes abnormally active. As a result, the body can start producing bone within soft tissues.

This process can occur in episodes called flare-ups. Trauma, surgery or other triggers can sometimes provoke inflammation and subsequent abnormal bone formation. The problem is that once mature bone has formed in these tissues, it can permanently restrict movement.

Also read: Rare Pregnancy Infections Linked To 3-Fold Higher Autism Risk: What Is TORCH?

More About The New Drug

Atebrioz contains zilurgisertib, an oral drug that blocks ALK2, the protein that is abnormally active in most people with FOP and triggers bone formation outside the skeleton.

The aim is not to remove bone that has already formed. Instead, the treatment is designed to reduce the formation of new abnormal bone.

FDA’s approval was based on a randomised, placebo-controlled trial involving 63 people with FOP. Participants received either zilurgisertib or placebo for 24 weeks, followed by an extension period.

At week 24, patients receiving Atebrioz had an average 3.2 cm³ decrease in the volume of newly formed abnormal bone, compared to a 24.6 cm³ increase in the placebo group. The FDA said the difference supported the drug’s effectiveness in reducing new heterotopic ossification.

Also read: Claude AI Discovers Novel CRISPR-Like Enzyme System: What Are The Implications For Gene Editing?

Symptoms & Treatment Of FOP

The disease can vary between individuals, but abnormal bone formation can progressively restrict movement. People with FOP may develop difficulty moving their neck, shoulders, spine, hips and other joints as new bone forms around them.

The condition can eventually affect mobility substantially. Extra bone formation can also interfere with everyday activities and contribute to severe disability.

Another characteristic feature is that people with FOP are often born with abnormalities of the big toes, which can help doctors recognise the rare condition early.

Atebrioz is not the first FDA-approved treatment for FOP. The FDA approved Sohonos (palovarotene) in 2023 as the first treatment for the disease.

More recently, the FDA approved Pasatru (garetosmab-grts) in August 2026, making Atebrioz the third FDA-approved treatment for FOP. The newer options differ in how they target the abnormal bone formation.

A confirmed case of mpox has been detected in Bunia, the capital of Ituri province in the Democratic Republic of Congo (DRC), where health authorities are already battling the country's largest-ever Ebola outbreak.

The development has raised concerns about the additional pressure on an already stretched outbreak response and the overall healthcare system.

The mpox case was confirmed after a 21-year-old woman was hospitalised with skin lesions that ae commonly seen in mpox.

The two viruses are not associated with each other, but the threat of two highly infectious diseases is now being navigated in the same area at the same time.

Mpox Case In Congo Amid Ebola Outbreak

Ituri is at the centre of one of the worst Ebola outbreaks the country has ever seen. As of September 23, the DRC reported 7,890 confirmed Ebola cases and around 3,799 deaths. The a case-fatality ratio, according to WHO, stayed put at 48.1%. Ituri, the epicenter of the outbreak, solely accounted for 6,032 confirmed cases.

The Ebola outbreak has also expanded geographically, with new cases reported across 63 health zones in seven provinces. The WHO says the continued spread is increasing the risk of cross-border transmission.

The appearance of mpox in Bunia, against the backdrop of Ebola, creates another challenge for surveillance, testing, infection prevention and safety of healthcare workers.

Also read: 1,370 Mpox Cases, 7 Deaths Reported In July: WHO Says Risk Remains Moderate

What Is Mpox?

Mpox is a viral disease that can cause fever, swollen lymph nodes, muscle aches, and peculiar rash or skin lesions. It spreads mainly through close physical contact with an infected person.

Some people recover without complications, while others can develop serious symptoms, particularly those with weak immune systems.

The newly case is especially alarming as the DRC had declared an end to mpox as a national public health emergency in April, following a three-year outbreak that resulted in more than 34,000 confirmed cases nationwide.

Also read: Canada Confirms Clade 1 Strain of Mpox: Know How It Impacts Human

Burden On An Already Overwhelmed Healthcare System

The two diseases are caused by different viruses and spread differently. A confirmed mpox case does not indicate that Ebola has mutated or that the two outbreaks are connected.

The WHO says the Ebola response is already operating under difficult conditions, with conflict, insecurity, population displacement and limited access to basic services hampering surveillance, contact tracing, infection prevention and timely care.

The concern is that health systems, that were already dealing with a major outbreak, now have another infection to detect, investigate and contain.

Bunia is not just another location where a case has been detected. It is the capital of Ituri, where the Ebola outbreak is the most concentrated.

WHO teams have described Bunia as a key operational hub for the response, with flights transporting healthcare workers, medicines and other supplies to affected regions.

The immediate priority will be investigation, contact tracing, and surveillance to determine whether the case is linked to a wider cluster.

DRC is already conducting extensive contact monitoring for Ebola. As of September 23, more than 32,000 people were listed for follow-up, depicting the scale of the response.

The US Food and Drug Administration has approved tavapadon, a once-daily oral medicine for adults with Parkinson’s disease. This has added a new option to Parkinson's treatment strategy that has long relied on drugs that mimic the brain’s dopamine supply. The drug will be sold in the US under the brand name Juvmo.

Tavapadon is different from traditional dopamine agonists because it selectively targets D1 and D5 dopamine receptors. It has been studied both as an early treatment and alongside levodopa in people with more advanced Parkinson’s disease and motor fluctuations.

Parkinson’s Disease & Dopamine

Parkinson’s disease is a progressive neurological disorder in which dopamine-producing nerve cells in a region of the brain called the substantia nigra disappear gradually.

Dopamine is essential for controlling movement. As its levels fall, people can develop symptoms like tremor, stiffness, slowness of movement and problems with balance.

This is why many Parkinson’s treatments entail increasing dopamine levels or mimicking its effects in the brain.

How Does Tavapadon Work?

Also read: Parkinson’s Is Rising Across US, But Not Equally: Why Are Some States Seeing More Cases Than Others?

Tavapadon is a selective D1/D5 partial dopamine agonist. It means that it does not simply increase the amount of dopamine in the brain. Instead, it binds to particular dopamine receptors and partially activates them, essentially helping reproduce some of dopamine’s signalling effects.

Most currently available dopamine agonists target D2/D3 receptors. Tavapadon’s D1/D5 is therefore one of its distinguishing characteristics. Researchers have been investigating whether this drug can can help provide motor symptom relief while avoiding some adverse effects linked with dopamine receptor activation.

The FDA’s approval was supported by the phase 3 TEMPO clinical programme. In TEMPO-1, which involved 529 people with early Parkinson’s disease, both 5 mg and 15 mg daily doses of tavapadon significantly improved motor function compared to placebo after 26 weeks.

The drug has also been studied in people already taking levodopa who experience motor fluctuations, a common problem with progressive Parkinson’s. In the TEMPO-3 trial involving 507 participants, adding tavapadon to levodopa increased daily 'on' time without troublesome dyskinesia compared to placebo.

As Parkinson’s disease progresses, some people taking levodopa experience periods when the medicine is working well and movement improves. This is called 'on' time. When the medication’s effect wears off and Parkinson’s symptoms return, it is called 'off' time.

Treatment aims to increase 'on' time while limiting troublesome involuntary movements, known as dyskinesia.

Side Effects Of Tavapadon?

Tavapadon was generally tolerated in the clinical trials, but it is not free of side effects. In the TEMPO-1 trial, the most commonly reported adverse events were:

• Nausea
• Headache
• Dizziness

The FDA’s approval follows data showing improvement in Parkinson’s symptoms, but longer-term safety remains an important factor that needs more investigation.

Dopamine agonists can also be associated with sleepiness, low blood pressure on standing, hallucinations and impulse-control disorders. These issues remain relevant when doctors consider where tavapadon fits into an individual’s treatment plan.

Tavapadon treats the symptoms of Parkinson’s disease. It does not restore the dopamine-producing nerve cells that have been lost or stop the neurodegenerative process.